Compare Medpace Holdings Inc (MEDP) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs T-Mobile Us Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 10.9× Medpace Holdings Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and T-Mobile Us Inc for 84 Days on average.
| MEDP | TMUS | |
|---|---|---|
Market Cap | $16.82B | $183.76B |
Volume | 223,093 | 4,294,650 |
Sector | Health | Media |
52-Week High | $630.19 | $230.06 |
52-Week Low | $393.42 | $161.73 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | $16.44B | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $88.31B in 2025. The company announced a 15% dividend hike and is advancing AI-driven 5G network upgrades, while maintaining robust profitability with a net margin of 11.45%.
Outlook remains positive given earnings momentum and strategic initiatives, but risks include high debt levels and competitive pressures. The consensus price target of $231.10 implies significant upside, supported by 79.6% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
